Abstract
Therapeutic plasma exchange is a method of treatment for clinical conditions that
represent diverse fields of medicine. The rationale for this mode of therapy is based
on sound mathematical modeling of the synthesis and removal of large molecules, usually
proteins, from the circulation. The basic assumptions underlying therapeutic plasma
exchange are that a clinical illness is caused by, or related to, a pathogenic substance
in the plasma, and that removing that substance from the plasma will alleviate the
patient’s illness. This approach has proven applicable to a wide variety of clinical
conditions. Therapeutic plasma exchange is largely a safe procedure in experienced
hands. The principal adverse effect, the hypocalcemic reaction, is readily ameliorated
or prevented.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Therapeutic plasma exchange.N Engl J Med. 1984; 310: 762-771
- Basic principles of therapeutic blood exchange.in: McLeod B.C. Szczepiorkowski Z.M. Weinstein R. Winters J.L. Apheresis: principles and practice. 3rd ed. AABB Press, Bethesda, MD2010: 269-293
- Treatment of Waldenström’s macroglobulinemia by plasmapheresis.N Engl J Med. 1960; 263: 574
- Plasmapheresis therapy in macroglobulinemia.Ann Intern Med. 1963; 58: 789
- Plasma-exchange: an overview.Plasma Ther. 1979; 1: 1-12
- Therapeutic intensive plasmapheresis.Semin Hematol. 1981; 18: 147-162
- Therapeutic apheresis. Applications and future directions.Vox Sang. 1983; 45: 261-277
- Plasmapheresis: Development and application in treatment of renal disorders.Artif Organs. 1986; 10: 324-330
- Plasmapheresis therapy of immunologic disease.Clevel Clin Q. 1980; 47: 53-72
- The role of therapeutic plasmapheresis in the rheumatic diseases.J Lab Clin Med. 1981; 97: 589-598
- Kinetics modeling of plasma exchange: intra- and post-plasma exchange.J Clin Apher. 1988; 4: 183-187
- Protein and biochemical changes during plasma exchange.in: Berkman E.M. Umlas J. Therapeutic hemapheresis. American Association of Blood Banks, Washington, DC1980: 13-52
- Analysis of immunoglobulin G kinetics in the non-steady state.J Lab Clin Med. 1985; 105: 312-320
- Panel IV. Dosage regimens for citrate anticoagulants.J Clin Apher. 1983; 1: 149-157
- A liquid calcium+vitamin D3 supplement is effective prophylaxis against hypocalcemic toxicity during apheresis platelet donation.J Clin Apher. 2018; 33: 60-64
- Complications of plasma exchange.Transfusion. 1989; 29: 124-127
- Complications of therapeutic plasma exchange: a recent assessment.J Clin Apher. 1994; 9: 1-5
- Frequency of immediate adverse effects associated with therapeutic apheresis.Transfusion. 1999; 39: 282-288
- Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures.J Clin Apher. 2001; 16: 130-133
- Pentastarch as partial replacement fluid for therapeutic plasma exchange: effect on plasma proteins, adverse events during treatment, and serum ionized calcium.J Clin Apher. 1999; 4: 114-121
- Prophylactic infusion of calcium gluconate to prevent a symptomatic fall in plasma ionized calcium during therapeutic plasma exchange: a comparison of two methods.J Clin Apher. 2018; 33: 600-603
- Optimization of infusional calcium gluconate for prevention of hypocalcemic reactions during therapeutic plasma exchange.J Clin Apher. 2019; 34: 656-660
- Prevention of citrate reactions during therapeutic plasma exchange by constant infusion of calcium gluconate with the return fluid.J Clin Apher. 1996; 11: 204-210
- Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome.Transfusion. 2000; 40: 896-901
- Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue.J Clin Apher. 2019; 34: 171-354
Article info
Publication history
Published online: February 24, 2023
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier Ltd. All rights reserved.
